Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes
Year: 2012
Type: article
Abstract: Four years ago, the Action to ControlCardiovascular Risk in Diabetes(ACCORD) trial was stopped early as the result of increased mortality asso-ciated with intensive glycemic treatment of a population with type 2 diabetes (T2DM) and high cardiovascular (CV) risk (1). Further reports have appeared from ACCORD (2) and other studies of high-risk populations, notably the Action in Di-
Source: Diabetes Care
DOI: 10.2337/dc12-0650
Authors: Matthew C. Riddle, Diane M. Karl
Institution: Oregon Health & Science University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Eli Lilly and Company, Sanofi
OpenAlex ID: W2133279372
